

Neuropathic Pain Market Poised for Significant Growth, Reaching \$13.3 Billion by 2032

PORTLAND, OR, UNITED STATES, March 11, 2025 /EINPresswire.com/ -- The global [neuropathic pain market](#), valued at \$7.7 billion in 2022, is projected to expand at a CAGR of 5.6%, reaching \$13.3 billion by 2032. This growth is fueled by increasing demand for neuropathic pain medications, rising awareness campaigns, and a surge in clinical trials for innovative treatments. Notably, Algiax Pharmaceuticals advanced its Phase 2a study for AP-325 in May 2023, showcasing the market's potential for groundbreaking therapies.



Get a Sample Copy of this Report: <https://www.alliedmarketresearch.com/request-sample/5447>

Key Market Insights

- By Drug Class: Anticonvulsants led the market in 2022, given their effectiveness in managing neuropathic pain.
- By Indication: Diabetic neuropathy dominated due to the rising prevalence of diabetes-related nerve damage.
- By Distribution Channel: Drug stores and retail pharmacies held the largest share, but online pharmacies are rapidly gaining traction due to e-commerce trends.
- By Region: North America led the market in 2022, yet Asia-Pacific is expected to witness the highest growth rate, driven by increasing healthcare accessibility and a rise in neuropathic pain cases.

Understanding Neuropathic Pain

Neuropathic pain originates from damage or disease affecting the somatosensory nervous system, causing abnormal sensations such as burning, coldness, numbness, or itching. Common treatments include:

- Anticonvulsants

- Opioids
- Capsaicin-based therapies
- Antidepressants

Market Dynamics: Drivers and Challenges

Market Drivers

- **Rising Chronic Disease Prevalence:** Conditions like diabetes, HIV, and cancer contribute to an increasing demand for neuropathic pain treatments.
- **Example:** 39 million people worldwide were living with HIV in 2022, a condition often associated with neuropathic pain.
- **Aging Population:** Older adults are more prone to conditions like diabetic neuropathy and shingles, contributing to neuropathic pain cases.
- **Increased Cancer Incidence:** Chemotherapy-induced peripheral neuropathy (CIPN) is rising as a side effect of cancer treatment.
- **Example:** 1.9 million new cancer cases were reported in the U.S. in 2021.

Market Challenges

- **Economic Downturns:** Recession-related budget constraints have impacted R&D investments in the pharmaceutical sector.
- **Example:** Deloitte reported a 1.2% return on pharma R&D investment in 2023, the lowest in 13 years.
- **High Drug Development Costs:** The average cost to develop a new drug surged to \$2.3 billion in 2022, slowing innovation.

Market Segmentation

By Drug Class

- **Anticonvulsants:** Held the largest market share in 2022.
- **Capsaicin:** Expected to experience the fastest growth due to its effectiveness in treating postherpetic neuralgia and diabetic neuropathy.

By Indication

- **Diabetic Neuropathy:** The highest revenue-generating segment in 2022.
- **Chemotherapy-Induced Peripheral Neuropathy (CIPN):** Expected to grow rapidly with increasing cancer cases.

By Distribution Channel

- **Drug Stores & Retail Pharmacies:** Dominated the market in 2022.
- **Online Pharmacies:** Poised for rapid growth due to increased convenience and digital adoption.

By Region

- **North America:** Led the market in 2022 due to strong healthcare infrastructure and R&D investments.
- **Asia-Pacific:** Expected to grow the fastest, driven by expanding healthcare access and a rising patient population.

Competitive Landscape

Leading players such as Abbott Laboratories, Pfizer Inc., and Eli Lilly and Company dominate the market. Key strategies include:

- **Acquisitions:** Collegium Pharmaceutical acquired the Nucynta Franchise for \$375 million in 2020, bolstering its U.S. market presence.
- **Partnerships:** Eli Lilly collaborated with Confo Therapeutics in 2023 to develop CFTX-1554, a non-opioid treatment for neuropathic pain.
- **Clinical Trials:** Grünenthal initiated Phase III trials for QUTENZA, a capsaicin-based treatment for post-surgical neuropathic pain.
- **Product Approvals:** The FDA approved QUTENZA in 2020 for treating diabetic peripheral neuropathy.

Future Outlook

The neuropathic pain market is poised for sustained growth, driven by:

- **Rising Chronic Disease Cases:** Increasing diabetes, cancer, and HIV prevalence will fuel demand.
- **Aging Population:** The expanding geriatric demographic will contribute to neuropathic pain cases.
- **Innovative Drug Developments:** Advancements in non-opioid therapies and targeted treatments will enhance treatment options.

Key Takeaways

- The neuropathic pain market is set to grow from \$7.7 billion in 2022 to \$13.3 billion by 2032.
- Anticonvulsants and diabetic neuropathy treatments lead the market.
- North America is the current leader, but Asia-Pacific is expected to witness the highest growth rate.
- Major players are focusing on acquisitions, partnerships, and clinical trials to drive innovation.

Despite economic uncertainties and high R&D costs, the neuropathic pain market remains a crucial segment of the global healthcare industry, offering promising opportunities for growth and innovation over the next decade.

Enquire Before Buying: <https://www.alliedmarketresearch.com/purchase-enquiry/5447>

David Correa

Allied Market Research

+15038946022 ext.

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/792815732>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.